SCHEMBL3615325

SCHEMBL3615325

CCNC(=O)C(CC1CCCCC1)NC(=O)OC(C)(C)C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 7/20 0.76
CTSK P43235 7/20 0.76
AAK1 Q2M2I8 2/20 0.51
CAPN1 P07384 1/20 0.49
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
CPB2 Q96IY4 3/20 0.47
REN P00797 2/20 0.43
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43
KMT2A Q03164 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRM1 Q13255 1/20 0.42
EPHX1 P07099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3615254 1.00 CTSS (0.76) CTSSCTSKAAK1CAPN1HDAC4
SCHEMBL1861303 0.88 CTSK (0.69) CTSSCTSKAAK1CAPN1HDAC4
SCHEMBL1861306 0.88 CTSK (0.69) CTSSCTSKAAK1CAPN1HDAC4
SCHEMBL28982692 0.87 CTSS (0.72) CTSSCTSKAAK1HDAC4HDAC1
SCHEMBL30172531 0.87 CTSS (0.76) CTSSCTSKAAK1HDAC4HDAC1
SCHEMBL28982690 0.87 CTSS (0.72) CTSSCTSKAAK1HDAC4HDAC1
SCHEMBL3819122 0.87 CTSS (0.72) CTSSCTSKAAK1HDAC4HDAC1
SCHEMBL482062 0.86 CTSK (0.70) CTSSCTSKAAK1HDAC4HDAC1
SCHEMBL8283416 0.86 CTSK (0.70) CTSSCTSKAAK1HDAC4HDAC1
SCHEMBL21427220 0.86 CTSK (0.70) CTSSCTSKAAK1HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487108-B2 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-07-16 US disclosed
EP-1966139-B1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS INC (US) 2011-12-21 EP disclosed
US-20100048636-A1 Aspartic Protease Inhibitors VITAE PHARMACEUTICALS, INC. 2010-02-25 US disclosed
EP-1966139-A1 ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2008-09-10 EP disclosed
WO-2007070201-A1 ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048636-A1 Aspartic Protease Inhibitors DNPEP, PEPD, SERPINB1 CTSS 95/4885CTSK 152/4885AAK1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.